Runlan Huo

540 total citations · 1 hit paper
10 papers, 472 citations indexed

About

Runlan Huo is a scholar working on Oncology, Pharmacology and Rheumatology. According to data from OpenAlex, Runlan Huo has authored 10 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Pharmacology and 3 papers in Rheumatology. Recurrent topics in Runlan Huo's work include Drug Transport and Resistance Mechanisms (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Folate and B Vitamins Research (3 papers). Runlan Huo is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Folate and B Vitamins Research (3 papers). Runlan Huo collaborates with scholars based in United States, China and Sweden. Runlan Huo's co-authors include Ke Li, Menghuan Li, Kaiyong Cai, Zhong Luo, Haitao Ran, Lu Lu, Yanhua Hou, Yang Cao, Qiufang Chen and Linawati Sutrisno and has published in prestigious journals such as ACS Nano, Journal of Pharmacology and Experimental Therapeutics and Journal of Pharmaceutical Sciences.

In The Last Decade

Runlan Huo

7 papers receiving 466 citations

Hit Papers

Engineering of a Nanosized Biocatalyst for Combined Tumor... 2018 2026 2020 2023 2018 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Runlan Huo United States 5 388 226 170 138 42 10 472
Chang Du China 13 436 1.1× 188 0.8× 236 1.4× 154 1.1× 84 2.0× 19 558
Haina Tian China 13 402 1.0× 200 0.9× 218 1.3× 108 0.8× 56 1.3× 27 528
Yanjuan Gu Hong Kong 13 301 0.8× 230 1.0× 121 0.7× 146 1.1× 46 1.1× 22 520
Fathelrahman Mohammed China 9 321 0.8× 153 0.7× 217 1.3× 118 0.9× 70 1.7× 9 447
Zhongqian Xi Germany 8 346 0.9× 243 1.1× 112 0.7× 136 1.0× 46 1.1× 11 489
Xiaomin Ma China 7 375 1.0× 262 1.2× 186 1.1× 91 0.7× 52 1.2× 8 564
Jianxian Ge China 12 328 0.8× 199 0.9× 247 1.5× 106 0.8× 97 2.3× 26 586
Nengyi Ni Singapore 11 257 0.7× 164 0.7× 125 0.7× 119 0.9× 40 1.0× 20 429
Yunyan Su China 8 255 0.7× 184 0.8× 150 0.9× 90 0.7× 28 0.7× 8 379

Countries citing papers authored by Runlan Huo

Since Specialization
Citations

This map shows the geographic impact of Runlan Huo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Runlan Huo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Runlan Huo more than expected).

Fields of papers citing papers by Runlan Huo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Runlan Huo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Runlan Huo. The network helps show where Runlan Huo may publish in the future.

Co-authorship network of co-authors of Runlan Huo

This figure shows the co-authorship network connecting the top 25 collaborators of Runlan Huo. A scholar is included among the top collaborators of Runlan Huo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Runlan Huo. Runlan Huo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Yee, Sook Wah, Jia Yang, Claire M. Brett, et al.. (2025). Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2). Clinical Pharmacology & Therapeutics. 118(1). 177–189. 1 indexed citations
3.
Nishii, Rina, Yongjun Xue, Runlan Huo, et al.. (2025). Evaluating the utility of endogenous OCT2 and MATE1/2-K biomarkers for DDI assessment in early clinical settings. Journal of Pharmaceutical Sciences. 114(12). 103776–103776.
4.
Huo, Runlan, Yueping Zhang, Weiqi Chen, et al.. (2024). A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants. Journal of Pharmacology and Experimental Therapeutics. 390(2). 162–173. 11 indexed citations
5.
Xue, Yongjun, Runlan Huo, Mu Chen, et al.. (2024). 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential. Drug Metabolism and Disposition. 52(9). 966–974. 3 indexed citations
6.
Zhang, Yueping, Petia Shipkova, Bethanne M. Warrack, et al.. (2023). Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo. Drug Metabolism and Disposition. 51(7). 851–861. 11 indexed citations
7.
Zhou, Jun, Menghuan Li, Yanhua Hou, et al.. (2018). Engineering of a Nanosized Biocatalyst for Combined Tumor Starvation and Low-Temperature Photothermal Therapy. ACS Nano. 12(3). 2858–2872. 390 indexed citations breakdown →
8.
Zhou, Jun, Menghuan Li, Wei Qi Lim, et al.. (2017). A Transferrin-Conjugated Hollow Nanoplatform for Redox-Controlled and Targeted Chemotherapy of Tumor with Reduced Inflammatory Reactions. Theranostics. 8(2). 518–532. 51 indexed citations
9.
Wei, Liping, et al.. (2012). Aureococcus anophagefferens growth potential affected by coastal water toxicants. Journal of Applied Phycology. 25(1). 145–152. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026